Loading company financials…
NYSE · Pharmaceutical Preparations · CIK 0000078003
$28.45
+1.75% · delayed 15 min
$161.24B market value
What this company does
PFIZER develops and makes medicines. It took in $62.58B last year, which makes it a very large company. Of every dollar it sells, about 12 cents is left as profit.
Financial health
Generally healthy, with a few things to watch.
From PFIZER INC's FY2025 annual filing · share price scored separately
Every check behind the three models, and what each one tests
Measured against FY2024, from the 10-K
Improved: +2.4 pts
71.9% to 74.3%
Deteriorated: -7.7%
$9.84B to $9.07B
Deteriorated: +7.4%
$57.41B
It makes a profit rather than burning through money.
$7.77B earned last year
Day-to-day operations generate real cash, not just accounting profit.
$11.70B cash from operations
Sales are shrinking rather than growing.
down 1.6% on last year
Filter by minute, hour, day or week
Loading price history…
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 2.6% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 12 cents of every dollar of sales as profit, earning $7.77B last year.
What it earns, what it keeps, and what it costs to run — all from the same filing
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it earned $7.77B and generated $11.70B of cash from operations.
Reported annual figures
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Nothing recent
No insider trades, pending-sale notices or 5% stake filings from PFE in the last few months. That is the ordinary case, not a gap.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Go deeper
Every figure above traces back to one of these filings.
Straight from SEC EDGAR — the original source for every figure above
| Filing | Filed | Covers to |
|---|---|---|
| Quarterly report(10-Q) | 2026-08-04 | 2026-06-28 |
| Major event announcement(8-K) | 2026-08-04 | 2026-08-04 |
Financial figures are from PFE's 10-K for fiscal year 2025 (period ending 2025-12-31), reported under the US GAAP taxonomy. View the source filing.
6 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
2.06
In the grey zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.52
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: +9.5%
$1.04B to $1.14B
Changed: -9.6%
$2.91B to $2.63B
4 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Nothing here reads the management commentary, which is where a company explains its own numbers.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
No. Sales shrank 1.6% last year.
Manageable, but notable. Clearing its debt would take about 5.4 years of cash flow. For every $1 it owes, it owns $1.71 in assets.
Around average. Investors pay $20.7 for every $1 of yearly profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
At a glance
| Major event announcement(8-K) | 2026-06-18 | 2026-06-18 |
| Major event announcement(8-K) | 2026-06-18 | 2026-06-18 |
| Quarterly report(10-Q) | 2026-05-05 | 2026-03-29 |
| Major event announcement(8-K) | 2026-05-05 | 2026-05-05 |
| Major event announcement(8-K) | 2026-04-27 | 2026-04-23 |
| Shareholder voting information(DEF 14A) | 2026-03-12 | 2026-04-23 |
| Annual report(10-K) | 2026-02-26 | 2025-12-31 |
| Major event announcement(8-K) | 2026-02-03 | 2026-02-03 |
| Major event announcement(8-K) | 2025-12-16 | 2025-12-16 |
| Major event announcement(8-K) | 2025-11-21 | 2025-11-18 |
| Major event announcement(8-K) | 2025-11-13 | 2025-11-13 |
| Quarterly report(10-Q) | 2025-11-04 | 2025-09-28 |
| Major event announcement(8-K) | 2025-11-04 | 2025-11-04 |
| Quarterly report(10-Q) | 2025-08-05 | 2025-06-29 |
| Major event announcement(8-K) | 2025-08-05 | 2025-08-05 |
| Major event announcement(8-K) | 2025-05-19 | 2025-05-14 |
| Quarterly report(10-Q) | 2025-05-05 | 2025-03-30 |
| Major event announcement(8-K) | 2025-04-29 | 2025-04-29 |
Coverage from the last 30 days
Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now
Yahoo Finance ·
This Is What I'd Do With Pfizer Stock Right Now
Yahoo Finance ·
Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva
Yahoo Finance ·
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo Finance ·
Pfizer’s Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?
Yahoo Finance ·
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
Yahoo Finance ·
Pfizer (PFE) Stock Looks Fully Valued As Earnings Run Ahead Of Value
Yahoo Finance ·
Pfizer (PFE) After FDA Vaccine Approval Faces A Fair Value Reality Check
Yahoo Finance ·
3 Things You Need to Know If You Buy Pfizer Stock Today
Yahoo Finance ·
Pfizer (PFE) Up 12.4% Since Last Earnings Report: Can It Continue?
Yahoo Finance ·
Pfizer's Pipeline Strategy Centers on Obesity and Oncology
Yahoo Finance ·
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
Yahoo Finance ·
Primary sources and further research